Authors: Jamsheed Javid Rashid Mir P K Julka P C Ray Alpana Saxena
Publish Date: 2015/01/13
Volume: 36, Issue: 6, Pages: 4253-4260
Abstract
Nonsmall cell lung cancer has a devastating prognosis and markers enabling a precise prediction of therapy response have long remained scarce Better treatment monitoring would allow an individual’s more effective patient adjusted therapy with lesser side effects and good clinical outcomes In the present study we monitored the serum cytochrome c levels pre and postchemotherapy of nonsmall cell lung cancer patients Using highly sensitive enzymelinked immunosorbent assay we evaluated cytochrome c levels in serum of 100 nonsmall cell lung cancer and 100 healthy controls We observed about threefold lower serum cytochrome c level in newly diagnosed nonsmall cell lung cancer patients than healthy individuals Patients in advanced stages and grade 3 histological differentiation showed significantly low level of serum cytochrome c and the lower levels were associated with worse survival outcome of nonsmall cell lung cancer patients In addition serum cytochrome c level was observed to be more than 13fold higher after first cycle of conventional chemotherapy wherein patients with higher level of serum cytochrome c before any therapy showed better response to chemotherapy in terms of significantly higher level of serum cytochrome c after first cycle of chemotherapy than patients with low level of serum cytochrome c at the time of diagnosis Detection of serum cytochrome c levels at the time of diagnosis may be useful in suggesting disease severity and prognosis of the nonsmall cell lung cancer patients Monitoring of serum cytochrome c might also serve as a sensitive apoptotic marker in vivo reflecting chemotherapyinduced cell death burden in patients with nonsmall cell lung cancer
Keywords: